Anti-CDH17/Exatecan Antibody-drug Conjugate ARR-217

**Semantic type:** Pharmacologic Substance

**Definition:** An antibody-drug conjugate (ADC) composed of a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the tumor-associated antigen (TAA) cadherin-17 (CDH17) site-specifically conjugated to the topoisomerase-1 inhibitor exatecan, with potential antineoplastic activity. Upon administration, anti-CDH17/exatecan ADC ARR-217 selectively targets and binds to CDH17-expressing tumor cells. Upon binding and internalization, exatecan is released and inhibits DNA topoisomerase 1 activity, thereby inhibiting DNA replication and resulting in cell cycle arrest and apoptosis in tumor cells expressing CDH17. CDH17, a member of the 7D-cadherin superfamily and a cell surface adhesion protein, is overexpressed in a variety of tumors of the gastrointestinal (GI) tract.

**Synonyms:** - ADC ARR-217 - ARR 217 - ARR-217 - ARR217 - Anti-CDH17 ADC HS-20110 - Anti-CDH17 Antibody-drug Conjugate ARR-217 - Anti-CDH17 Antibody-drug Conjugate MRG007 - Anti-CDH17/Exatecan ADC ARR-217 - Anti-CDH17/Exatecan Antibody-drug Conjugate MRG007 - Anti-cadherin-17 ADC ARR-217 - CDH-17 targeted ADC ARR-217 - MRG 007 - MRG-007 - MRG007